Mills & Reeve is excited to have advised F-star Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, on its successful merger with Spring Bank Pharmaceuticals, Inc (a company listed on Nasdaq), which completed 20 November 2020.
The merger positions the enlarged group to drive further growth and development towards effective cancer treatments.
John Fitzpatrick, Senior Vice President and General Counsel of F-star, said: “A huge thanks to the team at Mills & Reeve for their hard work and support which was critical in enabling us to achieve this deal – their transactional and sector knowledge proved invaluable with the transaction”.
James Fry, head of Mills & Reeve’s life sciences practice and F-star relationship partner, said: “We are delighted to have supported F-star on this strategic transaction. We’ve really enjoyed working with both the F-star and Mintz Levin teams to deliver this important milestone”.
The deal was led by corporate partners Stephen Hamilton and Jonathan Greenwood with key support from Kristian Shearsby, Sofie de Pfeiffer, Tom Samuel and Emma Wilson. Mills & Reeve’s transaction team acted alongside F-Star’s US advisers Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. See more details of the deal here. See more details of the deal here.